ArticleJournal of the American Medical Directors Association2026
Exposure to Drugs Related to Injurious Falls Risk and to Bisphosphonates in Nursing Home Residents With Recent Fracture.
Article in Journal of the American Medical Directors Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo describe the frequency of use of drugs related to injurious falls risk (DRIFR) and oral bisphosphonates in nursing home (NH) beneficiaries with Medicare fee for service and Part D who had sustained a recent fracture.
designThis is a cross-sectional study using data from January 1, 2017 to June 30, 2022. DRIFR included 18 medication classes. Use of DRIFRs and oral bisphosphonates was ascertained in the 30 days of NH care before a defined index date (day 31 for new residents; study start date for prevalent residents) using Part D claims. SETTINGS AND
participantsWe analyzed data from 14,559 NHs in the United States comprising 192,118 residents with a recent hip or other fracture, defined using a federally mandated clinical assessment (Minimum Data Set).
methodsPatient characteristics were identified from the most recent Minimum Data Set (≤92 days before index date). Descriptive statistics were calculated using t tests, Wilcoxon rank-sum test, or χ
resultsOf recent fractures, 41.4% of residents had hip fractures, and 67.7% had fractures at other sites. Mean age was 83.8 years (range, 65-110); 75.4% were female; 86.5% were non-Hispanic White. Osteoporosis was diagnosed in 18.8% of residents and was more common among those with bisphosphonate prescriptions than among those without. Only 4.2% of residents had bisphosphonate prescriptions, whereas 72.8% had prescriptions of DRIFRs. Common DRIFRs included statins (31.1%), opioids (26.7%), newer anticonvulsants (22.1%), and loop diuretics (22.1%). CONCLUSIONS AND IMPLICATIONS: Use of DRIFRs is common, whereas oral bisphosphonates are rarely prescribed in residents with a recent fracture receiving care in NHs. Our results suggest that opioids and newer anticonvulsants may represent common candidates for medication review. Efforts to treat fractures and prevent secondary fractures should not only focus on increasing bisphosphonate treatment but also on deprescribing DRIFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.